ERBB2 and breast cancer: In the first phase 2 study, alisertib monotherapy demonstrated a manageable safety profile in a cohort of 53 BC patients, with an ORR of 18% in HR+ or HER2+ BC patients resistant to ET, but minimal activity in TNBC.161